Suárez-Figueroa M, Contreras I, Noval S
Hospital Ramón y Cajal, Madrid, España.
Arch Soc Esp Oftalmol. 2006 Jul;81(7):405-7. doi: 10.4321/s0365-66912006000700009.
Intravitreal triamcinolone is being increasingly employed for the treatment of macular diseases. We report two cases of intraocular pressure elevation and cataract formation after intravitreal triamcinolone therapy, and wonder if these complications are more likely when this agent is used in young patients. Intravitreal triamcinolone was injected into both eyes of the two young patients with chronic posterior and intermediate uveitis refractory to peribulbar and oral corticosteroid therapy. Chronic cystoid macular edema improved in both patients, however the intraocular pressure increased, requiring topical antihypertensive therapy, and this was followed by accelerated cataract formation.
Young age and chronic inflammation could be associated with an intraocular pressure rise and subsequent cataract development after intravitreal triamcinolone.
玻璃体内注射曲安奈德越来越多地用于治疗黄斑疾病。我们报告了两例玻璃体内注射曲安奈德治疗后眼压升高和白内障形成的病例，并探讨了在年轻患者中使用该药物时这些并发症是否更易发生。对两名患有慢性后葡萄膜炎和中间葡萄膜炎的年轻患者，在球周和口服皮质类固醇治疗无效后，对其双眼进行了玻璃体内曲安奈德注射。两名患者的慢性黄斑囊样水肿均有改善，但眼压升高，需要局部抗高血压治疗，随后白内障加速形成。
年轻和慢性炎症可能与玻璃体内注射曲安奈德后眼压升高及随后的白内障发展有关。
